1. Martinez-Perez R, Moscote-Salazar LR, Deora H, Agrawal A. Letter: the safety and efficacy of continuous tirofiban as a monoantiplatelet therapy in the management of ruptured aneurysms treated using stent-assisted coiling or flow diversion and requiring ventricular drainage. Neurosurgery. 2019; Oct. 19. [Epub].
https://doi.org/10.1093/neuros/nyz459.
Article
2. Karan V, Vyas D, Bohra V, Huded V. Ticagrelor use in indian patients undergoing neuroendovascular procedures: a single center experience. Neurointervention. 2019; 14:125–130.
Article
3. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am CollCardiol. 2005; 45:246–251.
Article
4. Lemesle G, Landel JB, Bauters A, Delhaye C, Bonello L, Sudre A, et al. Poor agreement between light transmission aggregometry, Verify Now P2Y12 and vasodilatator-stimulated phosphoprotein for clopidogrel low-response assessment: a potential explanation of negative results of recent randomized trials. Platelets. 2014; 25:499–505.
5. Limaye K, Zanaty M, Hudson J, Nakagawa D, Al Kasab S, Alvarez C, et al. The safety and efficacy of continuous tirofiban as a mono-antiplatelet therapy in the management of ruptured aneurysms treated using stent-assisted coiling or flow diversion and requiring ventricular drainage. Neurosurgery. 2019; 85:E1037–E1042.
Article
6. Cattaneo M, Hayward CP, Moffat KA, Pugliano MT, Liu Y, Michelson AD. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost. 2009; 7:1029.
Article
7. Mrotzek SM, Rassaf T, Totzeck M. Ticagrelor leads to statin-induced rhabdomyolysis: a case report. Am J Case Rep. 2017; 18:1238–1241.
Article
8. Danielak D, Karaźniewicz-Łada M, Główka F. Assessment of the risk of rhabdomyolysis and myopathy during concomitant treatment with ticagrelor and statins. Drugs. 2018; 78:1105–1112.
Article